Core Scientific reported fourth‑quarter and full‑year 2025 results on March 2, 2026, with total revenue falling to $79.8 million—an 11.8% year‑over‑year decline that missed the consensus estimate of $90.4 million. The shortfall was driven largely by a sharp drop in digital‑asset self‑mining revenue, which fell as Bitcoin mining output decreased after the 2024 halving. In contrast, the company’s high‑density colocation segment grew 268% to $31.3 million, underscoring the strategic pivot toward AI‑centric data‑center services.
The earnings per share were a loss of $0.29, missing the consensus estimate of $-0.27. The negative figure reflects higher operating costs and the impact of a one‑time restatement of prior periods, which the company disclosed as a material weakness in internal controls. While the GAAP EPS of $0.42 beat expectations, the non‑GAAP figure highlights the company’s ongoing cash‑flow challenges, as reflected in a non‑GAAP adjusted EBITDA of $(42.7) million for the quarter versus $13.3 million a year earlier.
Management emphasized the progress of the colocation expansion, noting that the company is “now past the halfway point on our existing builds and scaling our colocation platform into a 1.5 gigawatt pipeline of leasable capacity. With a multi‑geography footprint and proven execution, we’re accelerating RFS timelines across multiple sites to position the company for durable growth.” The statement signals confidence in the AI and high‑performance computing markets, even as the company continues to navigate the transition from legacy Bitcoin mining.
Core Scientific’s restatement of 2024 and 2025 financials—stemming from improper capitalization of assets—has raised concerns about the reliability of its historical data. The identified material weakness in internal controls further compounds investor caution, as it may affect future audits and regulatory scrutiny. These factors, combined with the company’s heavy reliance on a few large contracts, particularly with CoreWeave, underscore the operational risks that accompany its strategic shift.
The mixed financial picture—revenue and EPS misses offset by robust colocation growth and improved gross profit—suggests that while Core Scientific is making headway in its new business model, it still faces significant cash‑flow and execution challenges. The restatement and control weakness, along with the dependency on a limited set of contracts, will likely remain key concerns for investors as the company continues to scale its AI‑focused infrastructure.
revised_sentiment_rating:-1
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.